Kunming Longjin Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 397.538 million compared to CNY 100.503 million a year ago. Operating income was CNY 835,356.71 compared to operating loss of CNY 3.432 million a year ago. Net income was CNY 4.872 million compared to net loss of CNY 1.606 million a year ago. Basic earnings per share from continuing operations was CNY 0.0122 compared to basic loss per share from continuing operations of CNY 0.004 a year ago.